← Leaderboards
David M Wilson
University Of California, San Francisco
$11,449,852
Attributed
$24,947,326
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,947,326 · 12
By mechanism
R01$24,059,076 · 10
R21$888,250 · 2
Top collaborators
- Michael Ohliger10 shared
- Sanjay Jain7 shared
- Charles Scott Craik4 shared
- Joanne N. Engel4 shared
- Michael John Evans4 shared
- John M Gerdes4 shared
- Henry F. Vanbrocklin4 shared
- Tejal A. Desai3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Michael Ohliger$3,943,738
- Sabrina Miriam Ronen$18,398,578
- Pavithra Viswanath$6,465,079
- Zhen Jane Wang$4,501,373
- Nicholas Jeremy Silva$484,008
Research focus
Positron-Emission TomographyImageIn VivoIn VitroCellsImaging ModalityAlzheimer&AposResponseRadiotracerSpecificityDosimetryTracerUptakeLabelPerformanceDiagnosisImmune ResponseSignal TransductionReportingBaseLeadBacteriaPre-ClinicalRadiologist
Grant awards (40)
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$804,521
R01 · FY2025 · AG · contact PI
Chemoenzymatic radiosyntheses of [18F]FDG-derived oligosaccharides for S. aureus detection$739,895
R01 · FY2025 · AI · contact PI
Imaging cerebral metabolic impairment in AD using Deuterium MRI$670,365
R01 · FY2025 · AG
Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking$659,855
R01 · FY2025 · CA
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$824,846
R01 · FY2024 · AG · contact PI
Chemoenzymatic radiosyntheses of [18F]FDG-derived oligosaccharides for S. aureus detection$780,034
R01 · FY2024 · AI · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$743,029
R01 · FY2024 · AI
Imaging cerebral metabolic impairment in AD using Deuterium MRI$685,840
R01 · FY2024 · AG
Sensing living P. aeruginosa using D-alanine derived radiotracers$663,113
R01 · FY2024 · EB · contact PI
Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking$626,733
R01 · FY2024 · CA
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$816,825
R01 · FY2023 · AG · contact PI
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$805,361
R01 · FY2023 · AI · contact PI
Imaging cerebral metabolic impairment in AD using Deuterium MRI$719,216
R01 · FY2023 · AG
Sensing living P. aeruginosa using D-alanine derived radiotracers$676,646
R01 · FY2023 · EB · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$660,398
R01 · FY2023 · AI
Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking$659,642
R01 · FY2023 · CA
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$809,270
R01 · FY2022 · AI · contact PI
First-in-Human evaluation of an astrocytic glutamate transporter (EAAT2) PET tracer in healthy and Alzheimer's diseased brain$784,058
R01 · FY2022 · AG · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$740,394
R01 · FY2022 · AI
Sensing living P. aeruginosa using D-alanine derived radiotracers$676,646
R01 · FY2022 · EB · contact PI
Diagnosis of low-grade glial tumors using 11C glutamine isotopomers$242,250
R21 · FY2022 · EB
Imaging bacterial infection using deuterium-enriched sugar alcohols.$201,875
R21 · FY2022 · AI · contact PI
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.$828,473
R01 · FY2021 · AI · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$691,499
R01 · FY2021 · EB · contact PI
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity$676,766
R01 · FY2021 · AI
Sensing living P. aeruginosa using D-alanine derived radiotracers$676,646
R01 · FY2021 · EB · contact PI
Imaging bacterial infection using deuterium-enriched sugar alcohols.$242,250
R21 · FY2021 · AI · contact PI
Diagnosis of low-grade glial tumors using 11C glutamine isotopomers$201,875
R21 · FY2021 · EB
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$719,894
R01 · FY2020 · EB · contact PI
Clinical translation of D-amino acid derived PET tracers for imaging spinalinfection$540,182
R01 · FY2020 · EB · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$658,515
R01 · FY2019 · EB · contact PI
Clinical translation of D-amino acid derived PET tracers for imaging spinalinfection$506,483
R01 · FY2019 · EB · contact PI
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections$674,697
R01 · FY2018 · EB · contact PI
Clinical translation of D-amino acid derived PET tracers for imaging spinalinfection$555,554
R01 · FY2018 · EB · contact PI
Clinical translation of D-amino acid derived PET tracers for imaging spinalinfection$559,121
R01 · FY2017 · EB · contact PI
Ascorbate-based biomarkers for predicting radiation response in prostate cancer$485,743
R01 · FY2016 · CA · contact PI
Ascorbate-based biomarkers for predicting radiation response in prostate cancer$484,813
R01 · FY2015 · CA · contact PI
Ascorbate-based biomarkers for predicting radiation response in prostate cancer$485,088
R01 · FY2014 · CA · contact PI
Ascorbate-based biomarkers for predicting radiation response in prostate cancer$468,859
R01 · FY2013 · CA · contact PI
Ascorbate-based biomarkers for predicting radiation response in prostate cancer$500,056
R01 · FY2012 · CA · contact PI